[Skip to Content]
[Skip to Content Landing]
April 18, 2007

Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock: Looking for the Reasons

Author Affiliations

Author Affiliations: Deutsches Herzzentrum, Technische Universität, Munich, Germany.

JAMA. 2007;297(15):1711-1713. doi:10.1001/jama.297.15.1711

Cardiogenic shock complicating acute myocardial infarction (AMI) is one of the most serious and challenging conditions in cardiovascular medicine, with up to two thirds of patients dying within a few weeks.1,2 According to data from a national registry of nearly 300 000 patients with ST-segment elevation AMI, the overall incidence of cardiogenic shock (diagnosed at both presentation and after admission) was 8.6%.3